Journal article
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux
Abstract
BACKGROUND: There is uncertainty regarding the optimal adjunctive unfractionated heparin (UFH) regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) treated with fondaparinux.
OBJECTIVE: The aim of this study is to evaluate the safety of 2 dose regimens of adjunctive intravenous UFH during PCI in high-risk patients with NSTE-ACS initially treated with fondaparinux and …
Authors
Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht H-J; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J
Journal
American Heart Journal, Vol. 160, No. 6, pp. 1029–1034.e1
Publisher
Elsevier
Publication Date
December 2010
DOI
10.1016/j.ahj.2010.07.037
ISSN
0002-8703
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAdultAnticoagulantsCoronary AngiographyDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationElectrocardiographyFactor XFemaleFollow-Up StudiesFondaparinuxHeparinHumansInjections, IntravenousIntraoperative PeriodMaleMyocardial RevascularizationPolysaccharidesProspective StudiesTreatment OutcomeYoung Adult